EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 19th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of October 21, 2020, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Dr. Arthur Taveres (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
Non-Exclusive LICENSE AGREEMENTNon-Exclusive License Agreement • March 19th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
This Non-Exclusive License Agreement, effective as of November 13, 2020 (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 450 Brookline Ave., Boston, MA 02215, USA (“DFCI”) and X4 Pharmaceuticals, Inc. a Delaware corporation having a principal place of business at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134 (“Licensee”). Each of DFCI and Licensee may be referred to herein as a “Party” or collectively as the “Parties.”
AMENDMENT NO. 2 TO MASTER SERVICES AGREEMENTMaster Services Agreement • March 19th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This amendment no. 2 (the “Amendment No. 2”) to the Master Services Agreement by and between X4 Pharmaceuticals, Inc., a Delaware corporation with a business address at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134 (“X4”), and Aptuit (Oxford) Limited an Evotec company, incorporated in England and Wales, having an address at 111 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, England (the “Company”), dated February 19, 2016 as amended by Amendment No. 1 entered into on on 23rd November 2016 (collectively the “Agreement”), incorporated by reference herein, is effective on 18th February 2021(the “Amendment No. 2 Effective Date”).
